Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma I: Introduction01:28

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IL-25 Enhances B Cell Responses in Type 2 Inflammation Through IL-17RB Receptor.

Allergy·2025
Same author

Human skin CD141<sup>+</sup> dendritic cells regulate cutaneous immunity via the neuropeptide urocortin 2.

iScience·2023
Same author

Genome-wide meta-analysis implicates variation affecting mast cell biology in urticaria.

The Journal of allergy and clinical immunology·2023
Same author

Sphingosine-1-phosphate induces airway smooth muscle hyperresponsiveness and proliferation.

The Journal of allergy and clinical immunology·2023
Same author

Epithelial coxsackievirus adenovirus receptor promotes house dust mite-induced lung inflammation.

Nature communications·2022
Same author

Effects of non-steroidal anti-inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses: EAACI task force on eicosanoids consensus report in times of COVID-19.

Allergy·2022

Related Experiment Video

Updated: Jun 22, 2026

Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with &beta;-arrestin
13:45

Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin

Published on: December 23, 2010

Leukotriene E4: perspective on the forgotten mediator.

Tak H Lee1, Grzegorz Woszczek, Sophie P Farooque

  • 1MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, King's College London, London, United Kingdom. tak.lee@kcl.ac.uk

The Journal of Allergy and Clinical Immunology
|June 2, 2009
PubMed
Summary

Leukotriene E4 (LTE4) plays a key role in asthma, despite past neglect. New research highlights its unique potency in airway hyperresponsiveness and inflammation, suggesting novel therapeutic targets.

More Related Videos

Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
10:39

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

Related Experiment Videos

Last Updated: Jun 22, 2026

Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with &beta;-arrestin
13:45

Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin

Published on: December 23, 2010

Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
10:39

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

Area of Science:

  • Immunology
  • Pulmonology
  • Pharmacology

Background:

  • Leukotriene E4 (LTE4) is a stable cysteinyl leukotriene (CysLT) implicated in asthma pathogenesis.
  • LTE4 mediates key asthma features including bronchial constriction, hyperresponsiveness, eosinophilia, and increased vascular permeability.
  • Historically, LTE4 was overlooked due to low receptor affinity and potency in vitro compared to other CysLTs.

Purpose of the Study:

  • To re-evaluate the role and mechanisms of LTE4 in asthma.
  • To investigate LTE4's unique characteristics and potential for novel therapeutic targets.
  • To understand LTE4's differential effects in asthmatic airways, particularly in aspirin-sensitive disease.

Main Methods:

  • Review of existing literature and experimental data on LTE4.
  • Comparison of LTE4's activity with other CysLTs in functional assays.
  • Analysis of in vivo studies in animal models and human subjects with asthma.

Main Results:

  • LTE4 exhibits unique activities not fully explained by current CysLT(1) and CysLT(2) receptor knowledge.
  • LTE4 demonstrates significant potency in increasing airway responsiveness to histamine.
  • Asthmatic airways show marked in vivo hyperresponsiveness to LTE4, especially in aspirin-sensitive patients.

Conclusions:

  • LTE4 possesses distinct biological activities relevant to asthma.
  • The unique properties of LTE4 warrant further investigation beyond established CysLT pathways.
  • Further research into novel LTE4 receptors may reveal new therapeutic strategies for asthma management.